Nonprofit leader named executive director at largest eastern South Dakota animal shelter
The Sioux Falls Area Humane Society, the largest nonprofit animal shelter in eastern South Dakota, has named Jami Gates Grieve as its new executive director, according to a Monday media release.
Grieve will begin her new role on Feb. 24, after 18 years of nonprofit leadership experience with the American Cancer Society and Big Brothers Big Sisters of the Sioux Empire (renamed Climb in 2019 after consolidating with Lutheran Social Services) and two years as the membership director for the Greater Sioux Falls Chamber of Commerce.
Most recently, Grieve worked in employee benefits roles with Aflac and Midwest Employee Benefits Inc.
The previous Humane Society executive director, James Oppenheimer, vacated the role after about a year and a half to assume the role of CEO at the Sioux Falls YMCA last September. Chief Financial Officer Michelle Hentschel has served as the interim executive director since then and will continue in her role as CFO once Grieve begins in her new position.
More: New YMCA CEO hopes to 'positively impact' city through family, youth activities
'I think she'll be a great fit here,' Hentschel said. 'We have a fantastic, strong leadership team here, and I think she's going to complement them so well. We're excited to get going with her and just continue the great work that we have going on.'
Grieve, a Sioux Falls Washington High grad, earned her bachelor's degree in Business Administration and Management at the University of Sioux Falls and her Master's in Business Administration - Strategic Leadership at Dakota Wesleyan University.
Grieve has also served as a classroom volunteer with Junior Achievement of South Dakota, a Sanford Metro Consumer Advisory Council member and a selection committee member for the SIOUXPERHERO Citizen Recognition Program.
The makings of SIOUXPERHEROES: Council to recognize 'Siouxper' heroes, bring more positivity to Carnegie Town Hall
The Sioux Falls Area Humane Society, located at 3720 E. Benson Road, has been serving animals since 1919. The nonprofit organization takes in abandoned, abused and homeless animals and helps them find permanent homes through training, veterinary care and compassion.
According to Hentschel, the SFAHS currently houses 220 animals, including dogs, cats, guinea pigs and more. The organization remains committed to its mission and is projected to serve thousands of animals this year.
Thanks to the dedication of the SFAHS team, the last two years have broken records in how many animals were adopted - 4,437 last year and 3,807 in 2023. As of Thursday, 492 adoptions have already been completed this year, surpassing last year's numbers at this time.
The organization is funded through donations and bequests, special events, adoption fees and community fundraisers.
Anyone who wishes to help can donate pet food, make a financial contribution, purchase items from the humane society's shelter, Amazon or Chewy wish lists, become a foster and volunteer their time.
More: Sioux Falls Area Humane Society over capacity, unexpected equipment donation helps
Visitors can also fill out an application to meet the animals and maybe even find a new furry friend (or they choose you) through adoption. Adoptable animals are listed on the humane society's website at sfadopt.com.
This article originally appeared on Sioux Falls Argus Leader: Sioux Falls Area Humane Society names new executive director
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 hours ago
- Yahoo
If we want NC to be a great place to live, we all have to pay for it with taxes
Richard Bostic's May 29 editorial hit the nail on the head. The truth is you get what you pay for. If North Carolina Republicans, Independents and Democrats want good schools, highways and government services that benefit individuals and society (including housing assistance, environmental protection and disaster preparedness) and make our state a great place to live, we all have to pay for it. If we don't, we will reap what we sow. I am glad to pay my fair share in income taxes not just to get what I pay for but to benefit fellow citizens and build a future we can be proud of. John Saxon, Hillsborough The 100% tariff on Chinese electric vehicles and any additional tariffs Donald Trump may impose are hurting Americans and U.S. climate goals. We must eliminate these tariffs as soon as possible. Chinese EVs cost much less than American ones because of government subsidies and cheaper production. These tariffs force us to pay inflated prices for domestic EVs or stick with gas cars. How are Americans supposed to contribute to the fight against climate change when they can't afford low-emission vehicles? Chinese companies like BYD offer longer battery life, faster charging and hybrid systems that outlast most American models. Protectionist policy proponents fear that without these tariffs, American workers and automakers will be harmed. A solution would be to require Chinese automakers to establish plants in the United States. Workers will have even more job opportunities in a future-proof car market. Congress must end these tariffs. Americans deserve access to innovative, affordable electric vehicles while we fight climate change and strengthen our economy. Holton Mody, Chapel Hill Thank you for the May 29 edition's article on Scott Pelley's (CBS 60 Minutes) commencement address at Wake Forest University. I was inspired to stream it on C-Span and found it eloquent, inspirational, dynamic and reassuring. He wasn't afraid to voice the truth of what is happening today, unlike many who have compromised their integrity in fear. He supported his statements with facts, not in support of any political party, but for democracy. Wanda Easley, Cary We are deeply concerned about the proposed $2.7 billion cut — nearly 40% — to the National Cancer Institute's budget. As representatives of the American Cancer Society in Central and Eastern North Carolina, we know firsthand this funding saves lives. Federal investment in cancer research has led to every major treatment breakthrough over the last 50 years. Because of this support, more than 18 million cancer survivors are alive today in the U.S. Slashing funding would delay progress, limit innovation and hurt patients and families. Cancer doesn't discriminate. Cutting lifesaving research is a step backward we cannot afford. We urge people to contact their lawmakers. Protect cancer research. Richard Averitte, executive director American Cancer Society – Central & Eastern North Carolina, Raleigh Studies approximate that 18 per 100,000 people people are intersex, meaning they have male and female sex characteristics, and about 1.7% of people are born with some intersex traits, which can put them in a gray area of sexual identification and gender conformity. As newborns, many are, intentionally or unintentionally, falsely classified as male or female (some are correctly listed as intersex). Intersex has been documented throughout history. How does this fit in with many Christian institutions stating that there are only two sexes, and supporting policies that recognize only two sexes? T This is important to not only for LGBTQ+ communities, athletic and marriage issues but to all of us who care about discrimination. Marnie Cooper Priest, Raleigh Our don't confuse me with the facts president has done it again; chickening out on tariffs as markets deliver their verdict and chickening out with Putin every time. Trump is unable to stand his ground, let alone lead. All talk and no action, withering in every interaction with Putin. Instead of leading, Trump enables China to win the innovation race. By attacking our own academic institutions, drivers of innovation gave us the edge, Trump is following Sen. Joseph R. McCarthy's model to bully those in the U.S. It's no longer a place for the best and brightest. China seems to be benefiting from Trump's policies. Jacqueline Allen, Carrboro
Yahoo
7 days ago
- Yahoo
/C O R R E C T I O N -- Color Health/
In the news release, Color Health Presents Findings on National Telehealth-Based Cancer Screening Programs at ASCO 2025, issued June 2, 2025 by Color Health over PR Newswire, we are advised by a representative of the company that the first bullet should read "Colorectal Cancer (CRC) Screening Program: Launched in June 2024..." rather than "...Launched in June 2025..." as originally issued inadvertently. The complete, corrected release follows: Programs were designed in collaboration with the American Cancer Society CHICAGO, June 2, 2025 /PRNewswire/ -- Yesterday at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting, Color Health presented new findings on the effectiveness of two nation-wide, virtual-first screening programs for colorectal and lung cancer. These programs were designed to expand access to cancer screening and were developed in collaboration with the American Cancer Society. Aligned with the conference theme of "Driving Knowledge to Action: Building a Better Future," Color's Virtual Cancer Clinic is dedicated to delivering center of excellence cancer care to all patients, from screening to survivorship care. The research presented today at ASCO reflects a commitment to access and rigorous evaluation. Titled "Improving Access to Cancer Screening Through National Telehealth-Based Lung and Colorectal Cancer Screening Programs," the research highlights preliminary results from two initiatives aimed at reducing inequities in early cancer detection using a virtual-first model. "Despite strong evidence supporting the efficacy of cancer screening, many patients - particularly those in healthcare deserts - face logistical, financial, and systemic barriers," said senior author William L. Dahut, MD, Chief Scientific Officer for the American Cancer Society. "The programs demonstrate that telehealth can be a powerful tool to deliver equitable, scalable cancer screening." Program Highlights The Color free cancer screening programs based on ACS screening guidelines and analyzed by Color utilize a centralized digital interface for cancer risk assessments, patient education, home-based testing, and appointment scheduling. Color, through its physician-led team implementing the program, personalized recommendations and managed follow-up on results.1 Colorectal Cancer (CRC) Screening Program: Launched in June 2024, Color drives CRC testing through a closed-loop virtual clinical program. At-home fecal immunochemical tests (FIT) are distributed to eligible adults (ages 45–75) via community partners such as federally qualified health centers and libraries. Lung Cancer Screening Program: Initiated in November 2023, Color evaluates eligibility of individuals seeking lung cancer screening, enables low-dose CT scan scheduling, and ensures appropriate clinical follow-up of results through its virtual platform. Research Focus Determine patient-initiated interest and final eligibility for cancer screening Evaluate success of community partnerships and virtual care navigation to enable rapid, accessible cancer screening Determine outcomes of closed-loop, physician-led virtual cancer screening clinical management "This work demonstrates how we can reimagine cancer care as a service that meets people where they are - at home and in their communities," said co-author Rebecca Miksad, MD, MPH, Chief Medical Officer at Color Health. "By integrating virtual care with personalized support, we can bridge persistent gaps in access and bring evidence-based preventive care to those who need it most." "We believe we've shown what's possible when technology, public health, and community infrastructure come together to remove long-standing barriers to cancer prevention," said Miksad. "We are proud to work with the ACS to support innovative models that help ensure equitable access to life-saving cancer care delivery." The data demonstrate that telehealth-driven, community-based models can meaningfully deliver access to cancer screening. By reducing logistical barriers and offering personalized, virtual support and medical care, these programs represent a scalable strategy to close screening gaps nationwide. Poster Details Title: Improving access to cancer screening through national telehealth-based lung and colorectal cancer screening programs Abstract: 1549 Poster Board Number: 315 About Color Health Color Health is changing the way patients access cancer care through a first-of-its-kind, vertically integrated, and fully owned Virtual Cancer Clinic. Powered by a 50-state oncologist-led team of clinical experts, Color provides proactive, evidence-based care that is accessible to anyone, anytime, and at every step of the cancer journey. We partner with employers, health plans, unions, and government agencies to improve accessibility of early interventions, timely diagnosis, oncology care management, and survivorship care. Connect with Color on Twitter, LinkedIn, Facebook and 1 ACS does not provide clinical care. ACS does not endorse any product, service, or providers. Media ContactAndy Lily Peskincolor@ View original content: SOURCE Color Health
Yahoo
01-06-2025
- Yahoo
New research presents promising findings on colorectal cancer treatment and prevention
Colorectal cancer is the second most common cause of cancer deaths in the United States, according to the American Cancer Society. This year, the organization estimates that more than 150,000 Americans will be diagnosed with it and nearly 53,000 will die from it. New studies presented at the annual meeting of the American Society of Clinical Oncology, or ASCO, in the last few days offer promising findings for both pharmaceutical and lifestyle interventions, including the impact of diet and exercise. Diagnoses of colorectal cancer have been decreasing overall for decades, the American Cancer Society says, thanks in large part to better screening. But case rates are rising among younger adults, and research estimates that colorectal cancer will become the leading cause of cancer death among adults ages 20 to 49 by 2030. Earlier research has suggested that regular exercise can improve survival rates for colorectal cancer patients, and a new study – published in the New England Journal of Medicine and presented at the ASCO conference on Sunday – confirmed those findings with robust clinical trial data. Between 2009 and 2024, researchers followed nearly 900 colon cancer patients who had completed chemotherapy – half of whom received an informational booklet that encouraged them to adopt a healthy lifestyle with good nutrition and exercise the other half of whom were also matched with a physical activity consultant for three years. They found that there was a 28% reduction in the risk of recurrence or new cancer for patients on the exercise program, with a five-year disease-free survival rate of 80% for the group with an exercise consultant compared with 74% for the group who just received the booklet. In other words, the exercise program was found to prevent 1 out of every 16 patients from developing recurrent or new cancer. 'That magnitude is comparable to – and in many cases exceeds – the magnitude of benefit offered by a lot of our very good standard cancer drugs,' said Dr. Christopher Booth, a professor of oncology with Queen's University and co-author of the new study. 'Exercise really should be considered an essential component of treatment of colon cancer.' Work is still being done to understand why exercise can help reduce the risk of cancer, but experts say that it may have something to do with the ways exercise helps reduce inflammation in the body. Another new study presented at the ASCO conference on Sunday found that anti-inflammatory diets also helped improve survival rates for people with stage 3 colon cancer. Patients who consumed more anti-inflammatory diets – including coffee, tea and vegetables such as leafy greens – and engaged in higher levels of physical activity had a 63% lower risk of death compared to patients who consumed the most inflammatory diets – including things like red meat, processed meat, refined grains and sugar-sweetened beverages – and engaged in lower levels of physical activity, the study found. 'Actively, as a field, we're learning about the role of the immune system in cancer development, and inflammation is an immune response,' said Dr. Sara Char, a clinical fellow in Hematology and Oncology at Dana-Farber Cancer Institute and lead author of the study, and the rise of colorectal cancer cases in younger people suggests it's a critical piece of the puzzle. 'When we look at the incidence of colon cancer in younger individuals … that really suggests to us that there is something in the environment – either in the foods we eat, our lifestyles, the chemicals that could be in our foods, all sorts of different things – that are outside of just genetics alone that could be driving these rates,' she said. 'So it is incredibly important for us, as a field, to be thinking about how our diet and lifestyle impacts not just our risk of developing this cancer, but then how people fare after it.' Both Booth and Char said that colorectal cancer patients are often seeking ways to proactively manage their risk. 'I think that's it's very empowering for patients,' Booth said. 'It's also achievable for patients. This is a commitment, but it's something that patients can achieve.' In his study, an 'exercise prescription' was developed based on each individual's starting point. Most people were able to reach their target increase if they went for a brisk walk for about an hour three or four days per week, Booth said. Lifestyle interventions like exercise and diet are also 'sustainable for health systems,' he said, but it's key that the system helps support patients in accessing the resources needed for behavioral interventions. Another new study showed promising results that might represent a new standard-of-care for certain patients with advanced colon cancer. On Friday, drugmaker Pfizer presented data on a colorectal cancer drug, Braftovi, used in combination with a standard chemotherapy and an antibody drug. During the trial, the drug combo was shown to double the length of time patients with an aggressive form of colorectal cancer lived with treatment: an average of 30 months compared with 15 months using currently available treatments. Braftovi targets a mutation in a specific protein that can lead to abnormal cell growth, and it's already approved by the US Food and Drug Administration to treat some forms of cancer. The study, which was funded by Pfizer, published Friday in the New England Journal of Medicine. 'It's a targeted cancer therapy that really depends on knowing what's driving patients' cancer,' Pfizer CEO Dr. Albert Bourla told CNN. These targeted therapies are one of the biggest advancements in cancer treatment over the past two decades, he said, and it's easy to diagnose whether cancer patients have the specific mutation that Braftovi can treat. The latest data on treatment for colorectal cancer a 'very, very important finding,' Bourla said, and the drugmaker plans to seek additional approval to add the new indication to the drug's label.
